Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients

Li, Mi; Xiao, Xiubin; Liu, Lianqing; Xi, Ning; Wang, Yuechao; Dong, Zaili; Zhang, Weijing

doi:10.1016/j.yexcr.2013.07.020

Cited by 28 publications

(33 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3F), showing that the recognition spots were caused by specific molecular interactions. At force volume mode, AFM can also map the specific proteins on cell surface (Alsteens et al, 2010;Li et al, 2013b). Compared with force volume mode, PFT imaging has many advantages (such as larger scan size, faster scan time and better resolution) which significantly improve the efficiency of AFM force spectroscopy experiments.…”

Section: Discussionmentioning

confidence: 99%

“…Here we demonstrated the potential of PFT imaging in locating the specific membrane proteins on human cancer cells. Previous studies of characterizing the membrane distributions on cell surface via AFM force volume mode were performed in a small local area (such as 500 nm × 500 nm and 1 μm × 1 μm) on the cell surface (Alsteens et al, 2010;Li et al, 2013b) owing to the slow efficiency of force volume mode. Due to the fact that cell surface is highly heterogeneous and complex (various lipids molecules and proteins are organized on the cell membrane (Lingwood and Simons, 2010), mapping the molecules in a larger size on the cell surface is evidently meaningful for us to better understand the proteins on the cell surface.…”

Section: Cd20s Inmentioning

confidence: 99%

See 1 more Smart Citation

Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy

Xiao

Liu

et al. 2016

Journal of Immunological Methods

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Cd20s Inmentioning

confidence: 99%

Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy

Xiao

Liu

et al. 2016

Journal of Immunological Methods

Self Cite

View full text Add to dashboard Cite

“…Viewed from this aspect, directly investigating the behaviors of tumor cells from lymphoma patients will be of remarkable clinical impact. We have used AFM to probe the interactions between rituximab and CD20 on tumor cells prepared from clinical lymphoma patients under the fluorescence recognition of specific markers [5,[36][37][38], as shown in Fig. 5.…”

Section: Rituximab Actions On Patient Tumor Cellsmentioning

confidence: 99%

Section: Rituximab Actions On Patient Tumor Cellsmentioning

confidence: 99%

Applications of Atomic Force Microscopy in Exploring Drug Actions in Lymphoma-Targeted Therapy at the Nanoscale

Liu

et al. 2015

BioNanoSci.

Self Cite

View full text Add to dashboard Cite

Rituximab, a monoclonal antibody against the CD20 molecule expressed on B cells, has revolutionized the treatment of B cell lymphomas. The use of rituximab significantly improves the long-term survival rates of lymphoma patients. However, there are still many patients who develop resistance to rituximab. Hence, the urgent need is enhancing the potency of anti-CD20 antibodies beyond that achieved with rituximab to provide effective therapies for more patients. Traditional studies about the killing mechanisms of rituximab are commonly based on optical microscopy, which cannot reveal the detailed situations due to the limit of 200-nm resolution. Quantitatively investigating the actions of rituximab at the nanoscale is still scarce. The advent of atomic force microscopy (AFM) provides a powerful and versatile platform for in situ investigating the nanoscale behaviors of individual live cells. The applications of AFM in life sciences in the past decade have yielded a lot of novel insights into cell biology and related diseases. In this article, the typical applications (e.g., ultra-microstructures, mechanical properties, and molecular recognition) of AFM in investigating the three killing mechanisms of rituximab at the nanoscale are summarized; the challenges facing AFM single-cell assay and its future directions are also discussed.

show abstract

“…By using SMFS at force volume mode, we can also detect the distribution of membrane proteins on the cell surface [61]. At this mode, AFM tips carrying specific molecules (e.g., antibodies and ligands) were controlled to obtain arrays of force curves at the local areas on the cell surface.…”

Section: Mapping the Distribution Of Membrane Proteins On Tumor Cellsmentioning

confidence: 99%

Investigating the Molecular Specific Interactions on Cell Surface Using Atomic Force Microscopy

Liu

et al. 2015

Micro‐ and Nanomanipulation Tools

Self Cite

View full text Add to dashboard Cite

Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries [1]. The new cancer cases will increase from 12.7 million in 2008 to 22.2 million by 2030, while the cancer-related deaths will increase from 7.6 million in 2008 to 13.2 million by 2030 [2]. Carcinogenesis and tumor progression are complex and progressive processes that are associated with numerous genetic and epigenetic alterations [3]. Our growing understanding of tumor biology and genomics paves the way to the development of new therapy approaches, and marked progress has been achieved in overcoming treatment resistance through precision medicine and immunotherapy [4]. However, because of the fact that the exact reason why a cell becomes cancerous is unknown (the only one cancer whose cause is clear is cervical cancer), the current cancer treatments cannot prevent the recurrence of cancers and the age-adjusted mortality rate for cancer is about the same in the twenty-first century as it was 50 years ago [5].Lymphomas, solid tumors of the immune system [6], account for 4%-5% of all cancers [7]. Hodgkin's lymphoma accounts for about 10% of all lymphomas and the remaining 90% are referred to as non-Hodgkin lymphoma (NHL) [6]. NHL can be divided into many subtypes according to the combination of morphology, immunophenotype, genetic, molecular, and clinical features of the tumors [8]. Approximately, 85% of NHL in adults arises from B cells [9], and the rest are T-cell origin [10]. Follicular lymphoma and diffuse large B-cell lymphoma are the two most common B-cell NHLs, comprising 60% of new B-cell NHL diagnoses each year in North America [11]. In 1997, US Food and Drug Administration (FDA) approved rituximab (an anti-CD20 monoclonal antibody (mAb)) for treating B-cell NHLs. CD20 is 297 amino acids long with a molecule weight of about 33 kDa [12]. The exact biological function of CD20 is currently unknown [13], partly because it has no known natural ligand and CD20 knockout mice display an almost normal phenotype [14]. Many of the functions of CD20 have been determined using artificial ligands (antibody) [15]. In vitro experiments proposed that CD20

show abstract

Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients

Cited by 28 publications

References 56 publications

Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy

Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy

Applications of Atomic Force Microscopy in Exploring Drug Actions in Lymphoma-Targeted Therapy at the Nanoscale

Investigating the Molecular Specific Interactions on Cell Surface Using Atomic Force Microscopy

Contact Info

Product

Resources

About